Shares of Regeneron Pharmaceuticals Inc. slipped 3.03% to $545.94 Monday, on what proved to be an all-around poor trading ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Regeneron ...

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds ...

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

Regeneron has received a second complete response letter from the FDA for odronextamab and anticipates delays for Eylea HD ...

Our Health Care Litigation Team discusses a District of Massachusetts case holding that allows the government to switch liability theories in ...

Regeneron Court Permits Government to Pursue False Certification Theory - On August 4, the district court in the closely ...

Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, ...

Return on Equity (ROE): Regeneron Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds ...